NASDAQ · Biotechnology

NMRA (NMRA) Stock

$1.67 +3.42% NASDAQ: NMRA Healthcare

Valuation

MetricValue
Price$1.67
Market Cap$308.50M
P/E Ratio-1.19
P/B Ratio3.06
P/S Ratio0.00
EPS (TTM)$-1.45
52-Week High$3.65
52-Week Low$0.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-227.88%
ROA-124.08%
ROCE-231.73%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio5.97

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-237.0M$-136.0M$-188.0M$-263.0M$-241.0M
Net Profit$-237.0M$-131.0M$-236.0M$-244.0M$-237.0M
EPS$-1.56$-0.86$-1.49$-1.53$-1.45
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$429.0M$426.0M$496.0M$317.0M$191.0M
Total Liabilities$755.0M$873.0M$27.0M$30.0M$87.0M
Cash$409.0M$241.0M$374.0M$142.0M$183.0M
Borrowings$2.0M$8.0M$5.0M$2.0M$0

Latest News

RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk MT Newswires · Jul 13, 2026 Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation Simply Wall St. · Jul 11, 2026 Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy Insider Monkey · Jul 7, 2026 LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential Insider Monkey · Jul 2, 2026 Mizuho Adjusts Price Target on Neumora Therapeutics to $4 From $6, Maintains Outperform Rating MT Newswires · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-75.0M$-115.0M$-163.0M$-183.0M$-206.0M
Investing Cash Flow$-2.0M$-169.0M$64.0M$-71.0M$169.0M
Financing Cash Flow$1.0M$4.0M$-1.0M$8.0M$0
Net Cash Flow$217.0M$-167.0M$133.0M$-232.0M$39.0M
Free Cash Flow$-76.0M$-115.0M$-163.0M$-183.0M$-206.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-60.16%
Quick Ratio5.09
Interest Coverage-80.33
Return 1Y-15.68%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About NMRA

NMRA is led by CEO Daljit Singh Aurora, employs 110 people, headquartered in US, publicly traded since 2023.

NMRA stock trades at $1.67 with a market capitalization of $308.50M. The stock is valued at a price-to-earnings (P/E) ratio of -1.19, price-to-book of 3.06, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.72 and $3.65, and currently trades 54.2% below its 52-week high.

On profitability, NMRA generates a return on equity (ROE) of -227.88%, return on capital employed of -231.73%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides